



King's Research Portal

DOI:

[10.1016/j.yexcr.2018.01.016](https://doi.org/10.1016/j.yexcr.2018.01.016)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Yang, J., Xu, J., Danniell, M., Wang, X., Wang, W., Zeng, L., & Shen, L. (2018). The interaction between XBP1 and eNOS contributes to endothelial cell migration. *Experimental Cell Research*.

<https://doi.org/10.1016/j.yexcr.2018.01.016>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal


Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Author's Accepted Manuscript

The interaction between XBP1 and eNOS contributes to endothelial cell migration

Junyao Yang, Jing Xu, Martin Danniell, Xiaocong Wang, Wen Wang, Lingfang Zeng, Lisong Shen



PII: S0014-4827(18)30026-0
DOI: <https://doi.org/10.1016/j.yexcr.2018.01.016>
Reference: YEXCR10887

To appear in: *Experimental Cell Research*

Received date: 17 October 2017
Revised date: 3 January 2018
Accepted date: 12 January 2018

Cite this article as: Junyao Yang, Jing Xu, Martin Danniell, Xiaocong Wang, Wen Wang, Lingfang Zeng and Lisong Shen, The interaction between XBP1 and eNOS contributes to endothelial cell migration, *Experimental Cell Research*, <https://doi.org/10.1016/j.yexcr.2018.01.016>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The interaction between XBPI and eNOS contributes to endothelial cell migration

Junyao Yang^{1,2}, Jing Xu³, Martin Dannel², Xiaocong Wang², Wen Wang³, Lingfang Zeng² & Lisong Shen¹

1. Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
2. Cardiovascular Division, Faculty of Life Science and Medicine, King's College London, SE5 9NU London, United Kingdom
3. School of Engineering and Materials Science, Queen Mary, University of London, E1 4NS London, United Kingdom

Running title: *Interaction between XBPI and eNOS*

To whom correspondence may be addressed: Lingfang Zeng: Cardiovascular Division, Faculty of Life Science and Medicine, King's College London, London SE5 9NU, UK. Tel.: +44 20 7848 5270, Fax: +44 20 7848 5296, E-mail: lingfang.zeng@kcl.ac.uk or Lisong Shen: Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. E-mail: shenlisong@ximhuamed.com.cn

Key words: cell migration, endothelial cell, microRNA, nitric oxide synthase, X-box binding protein 1

Funding. This study was supported by grants from the National Natural Science Foundation of China (81401946)

Abstract:

The X-box binding protein 1 (XBPI) is a pivotal transcription factor in the endoplasmic reticulum stress response. Our previous studies have proven that XBPI is involved in vascular endothelial growth factor (VEGF)-mediated endothelial cell (EC) proliferation and angiogenesis. In this study, we used EC monolayer wound healing, tube formation and transwell migration models to explore the role of *XBPI* splicing in EC migration. We found that scratching on EC monolayer triggered *XBPI* splicing, which was attenuated by the presence of SU5416 and LY294002, suggesting that VEGF signalling pathways may be involved. Over-expression of the spliced XBPI (XBPIs) via Ad-*XBPI*s gene transfer increased while knockdown of *IRE1 α* or *XBPI* by ShRNA lentivirus suppressed EC migration. Over-expression of XBPIs up-regulated the nitric oxide synthase 3 (*NOS3*) mRNA through the 3'UTR-mediated stabilization and increased eNOS protein translation. Further experiments demonstrated that miR-24 participated in the XBPIs-induced eNOS up-regulation and EC migration. Further co-IP and immunofluorescence staining assays revealed that protein kinase B (Akt), eNOS and XBPIs form a complex, resulting in Akt and eNOS nucleus relocation. These results suggest that *XBPI* splicing can regulate eNOS expression and cellular location, leading to EC migration and therefore contributing to wound healing and angiogenesis.

Introduction

Cardiovascular disease is one of the leading causes of death worldwide. It is a multifactorial multi-step disease, in which the endothelium injury is the initial step of the disease development. Endothelial cells (ECs) are key cellular components of the blood vessels, forming an intact mono-layered structure of vasculature that acts as a semi-permeable barrier between body fluids and the tissues, which modulating vessel tone via nitric oxide production [1, 2]. Endothelium injury is usually caused by risk factors or mechanical forces-induced ECs apoptosis, leading to local permeability change and a series of inflammatory reactions. The adjacent EC proliferation and migration towards the denuded area plays an important role in vascular injury repair and prevention of cardiovascular disease development.

Endothelial nitric oxide synthase (eNOS) enzyme, encoded by the *NOS3* gene, is one of the three isoforms that synthesize nitric oxide (NO). NO produced by eNOS has the ability to promote vascular relaxation, antioxidant and anti-thrombus, which is essential to regulating vascular tone, cellular proliferation, leukocyte adhesion, and platelet aggregation [3-5]. As its attribution to NO production, eNOS plays an essential role in cardiovascular system protection [6].

MicroRNAs (or miRNAs) comprise a novel class of small, non-coding endogenous RNA molecules (about 22 nucleotides) that regulate gene expression by directing their target mRNAs for degradation or post-transcriptional regulation [7, 8]. MiR-24 is conserved in various species, and belongs to miR-23~27~24 cluster on human chromosome 9 and 19. MiR-24 has been shown to participate in regulation of vascular ECs proliferation, apoptosis, migration, inflammation and differentiation [9-11].

The X-box binding protein 1 (XBP1) is a transcriptional factor containing a unique basic-region leucine zipper (bZIP) domain, which was originally identified as its capability of binding to the cis-acting X-box presented in the promoter regions of human major histocompatibility complex class II genes [12]. Accumulating evidence showed that XBP1, downstream of the inositol requiring enzyme 1 alpha ($IRE1\alpha$), is a stress-inducible transcription factor that exists on both invertebrate and vertebrate cells and is crucial for cell survival under stress conditions [13-15]. In mammalian cells, XBP1 is a key signal transducer upon the endoplasmic reticulum (ER) stress response. XBP1 was reported to be associated with human disease such as metabolism disease, vascular disease and so on [16, 17]. Although ER stress is reported to be participated in vascular diseases [18-22], the role of XBP1 in vascular disease and its relationship to NO have not been well understood. In the current study, we demonstrated that EC monolayer injury via scratching induces *XBPI* splicing, which in turn up-regulates and interacts with eNOS, leading to eNOS nuclear translocation that promotes EC migration.

Results

1. Wound in EC monolayer induced *XBPI* splicing, which was involved in EC migration.

XBP1 exists as unspliced (XBP1u) and spliced (XBP1s) forms via $IRE1\alpha$ -mediated unconventional splicing [15, 23]. The *XBPI* splicing was shown to be involved in EC

proliferation and apoptosis[24, 25]. To test whether *XBPI* splicing is also involved in ECs migration, an endothelium damage model was mimicked *in vitro* by scratching a confluent human umbilical vein EC (HUVEC) monolayer, followed by the observation on cell migration and the assessment on *XBPI*s protein expression at 6h and 24h post-scratching. As shown in Figure 1A, the scratching activated *XBPI* splicing as revealed by Western blot analysis. In order to verify whether the vascular endothelial growth factor (VEGF) signaling pathway was involved in the scratching-induced *XBPI* splicing, selective inhibitors(SU1498, PD98059 or LY294002)were included.The quantitative RT-PCR with specific primer sets for *XBPIu* and *XBPIs* revealed that scratching decreased *XBPIu* but increased *XBPIs* mRNA levels, which was abolished by the inhibitors (Supplement 1). These results suggest that endothelium damage activates *XBPI* splicing in a VEGF signalling pathway dependent manner.

The endothelium damage normally triggers the adjacent ECs migration to the injured area. To assess whether the scratching-induced *XBPI* mRNA splicing contributes to EC migration, the gain-of-function (via Adenoviral transfer of *XBPIs*) and loss-of-function (via shRNA lentivirus-mediated knockdown of *XBPI* or *IRE1 α*) assays were performed in HUVEC scratching model. As shown in Figure 1B, the over-expression of *XBPIs* enhanced EC migration observed at 8h post scratching.The effect of Ad-*XBPIs* is shown in Supplement 1 B.As expected, the knockdown of either *XBPI* or *IRE1 α* attenuated the wound healing(Figure 1C&1D). Further experiments with the tube formation on Matrigel assays revealed that knockdown of *XBPI* or *IRE1 α* suppressed HUVECs basal and VEGF-induced tube formation (Figure 1E). These results suggest *XBPI* splicing indeed contributes to EC migration.

2. Wound in EC monolayer up-regulated eNOS expression in an *XBPI* splicing-dependent manner.

Previous studies have shown that NO is a potent inducer of ER stress[26, 27], and eNOS has been shown to be involved in angiogenesis by supporting EC migration[28]. Thus, we wondered whether there was a crosstalk between *XBPI* splicing and eNOS in scratching-induced wound healing. The eNOS protein levels and NO production were firstly detected following scratching of a confluent HUVEC monolayer. As shown in Figure 2A, eNOS protein level was dramatically increased at 6h post-injury and then gradually returned to the basal level as the incubation time proceeded. As expected, NO production of the culture medium was increased by scratching (Figure 2B). However, there is a time delay between

NO production and eNOS protein increase (Figure 2A versus Figure 2B). Further experiments revealed that the eNOS protein level increase might be due to *NOS3* mRNA increase, which was VEGF signalling dependent (Figure 2C). We chose 3 different VEGF signalling pathway inhibitors. SU1498, is a selective inhibitor of the VEGFR2, having negligible activity at several other serine/threonine and tyrosine kinases[29]. PD98059 is a potent and selective inhibitor of MAP kinase kinases (MAPKK), MEK1 and MEK2 by binding to the inactive form of MAPKK and prevents activation by upstream activators, which can be used to study the role of MAPKK signalling[30]. LY294002 is a potent, cell permeable inhibitor of phosphatidylinositol 3-kinase (PI3K) that acts on the ATP binding site of the enzyme[31].

As described above, both *XBPI* splicing and *NOS3* expression were up-regulated by the scratching, there might be direct link between these two events. To test this, the *XBPI* expression and splicing were down-regulated via shRNA-mediated *XBPI* and *IRE1 α* knockdown respectively prior to the scratching experiments. As shown in Figure 2D and 2E, the scratching-induced up-regulation of *NOS3* mRNA (Figure 2D) and eNOS protein (Figure 2E) was abolished by knockdown of either *XBPI* or *IRE1 α* . Further experiments with a tetracycline/doxycycline inducible system (Ad-*TRE-XBPIs* plus Ad-*Tet-on*) revealed that over-expression of *XBPIs* in HUVECs could increase eNOS protein level (Figure 2F) and NO production (Figure 2G). These results suggest that *XBPI* splicing is sufficient and essential for endothelium damage-induced eNOS upregulation.

3. *XBPIs* increased *NOS3* mRNA stability via down-regulating microRNA *miR-24*.

The upregulation of an mRNA molecule can be derived from an increase of its transcription or stability or both. As *XBPIs* is an intact transcription factor, the up-regulation of eNOS by *XBPIs* may be due to transcriptional regulation. To test this, the effect of *XBPIs* on the *NOS3* promoter reporter expression (pGL3-*NOS3*-Luc reporter) was assessed. Surprisingly, overexpression of *XBPIs* significantly decreased the reporter gene expression (Figure 3A). *XBPI* and mature activating transcription factor 6 (ATF6N), another ER stress transducer (28) exerted a slightly inhibitory effect on *NOS3* promoter reporter expression (Figure 3A). These results imply that *XBPI* splicing may increase *NOS3* mRNA stability. It has been established that the 3' untranslated region (3'UTR) plays an important role in mRNA stability. To test whether *XBPI* splicing stabilises *NOS3* mRNA through its 3'UTR, the *NOS3* mRNA 3'UTR was cloned into pSiCHECK2 reporter system. There are different *NOS3* transcript variants with two types of 3'UTR, for which the transcript variants

tv1 and tv4 are the representatives. Both 3'UTRs (*TV1-3'UTR* and *TV4-3'UTR*) were cloned and their response to XBP1s was assessed in HUVECs. As shown in Figure 3B, over-expression of XBP1s significantly increased the reporter gene expression, indicating that XBP1s can increase *NOS3* mRNA stability.

microRNAs (miRNAs) are a group of short non-coding RNAs, capable of regulating mRNA stability via binding to mRNA 3'UTR. Through electronic analysis of the potential miRNA target sequences with the RNAwalk software, we found that *hsa-miR-24*, *hsa-miR-125* and *hsa-miR-214* possessed potential binding elements in both *TV1-* and *TV4-* 3'UTR. Quantitative RT-PCR analysis of these miRNAs following scratching revealed that all three miRNAs were dramatically down-regulated (Figure 3C). To test whether the down-regulation of these miRNAs was due to transcriptional suppression or increased degradation, exogenous miRNA mimics were introduced into HUVECs, followed by scratching and assessment of the miRNA levels. Compared to endogenous miRNAs, the transfection of exogenous miRNA mimics induced a huge accumulation of the miRNAs (Figure 3D). Interestingly, scratching of the ECs significantly decreased amount of exogenous *miR-125* and *miR-214*, while had no effect on exogenous *miR-24* (Figure 3D). Further experiments revealed that over-expression of XBP1s significantly decreased *miR-24* level but had no effect on the other two miRNAs (Figure 3E). These results suggest that there are different mechanisms involved in the regulation of *miR-24* and the other two miRNAs.

As all three miRNAs have potential binding elements in *NOS3* 3'UTR and are down-regulated by scratching, it is possible that their down-regulation contributes to *NOS3* stabilisation. To test this, exogenous miRNA mimics were introduced into ECs and subjected to scratching, followed by *NOS3* mRNA analysis. As shown in Figure 3F, only the exogenous *miR-24* mimics (premiR24) abolished scratching-induced *NOS3* up-regulation, while the other two miRNAs had no effect. Similarly, only the exogenous *miR-24* mimics but not the other two ablated XBP1s-induced eNOS protein (Figure 3G). These results suggest that the XBP1s-mediated down-regulation of *miR-24* contributes to *NOS3* mRNA and eNOS protein up-regulation.

4. miR-24 attenuated XBP1s-induced EC migration

To further explore whether the down-regulation of *miR-24* contributes ECs migration, *miR-24* mimics (premiR24) were introduced into HUVECs and infected with Ad-XBP1s virus to over-express XBP1s, followed by EC migration assays with transwell and

wound healing models. As shown in Figure 4A and 4B, the XBP1s-induced EC migration was significantly attenuated by exogenous *miR-24*, suggesting that the down-regulation of *miR-24* contributes to XBP1s-induced EC migration.

5.eNOS was involved in EC migration via forming a complex with AKT and XBP1s.

It has been reported that the eNOS/NO/Akt signalling pathway contributes to endothelium damage-induced EC migration[32, 33]. As described above, endothelium damage up-regulates eNOS and NO production via XBP1ssplicing. Our previous study has demonstrated that XBP1s can activate Akt phosphorylation[25]. Thus, we wonder whether NO production and Akt activation contribute to XBP1s-induced EC migration. To test this, the eNOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME)[34], PI3K inhibitor LY294002 and PKG inhibitor KT5823 were used to inhibit NO production and Akt activation, respectively. As shown in Figure 5A and supplement 2, LY294002 but not L-NAME or KT5823 abolished XBP1s-induced EC migration, suggesting that NO production is not involved in XBP1s-induced EC migration. However, knockdown of *NOS3* by siRNA fully attenuated XBP1s-induced EC migration (Figure 5B). As L-NAME is eNOS function (producing NO) inhibitor, not eNOS protein inhibitor, these results suggested that eNOS protein is essential for XBP1s-induced EC migration. Immunoprecipitation assay pulled down XBP1s, Akt and eNOS together in XBP1s over-expressed cell (Figure 5C), indicating that these three proteins may form a complex. In order to identify the complex formation, VEGF stimulation was introduced and completed immunoprecipitation assay pulled down XBP1s, Akt and eNOS together (Supplement 3A). Furthermore, immunofluorescent staining revealed that Akt and eNOS were relocated into the nucleus in the Ad-XBP1s infected cells (Fig. 5D), and the similar trend are detected in scratching and VEGF stimulated HUVECs (Supplement 3B and 3C). These results suggest that XBP1s, Akt and eNOS may form a complex in the nucleus.

Discussion

Endothelium damage is the initial step of the development of multiple cardiovascular diseases. The adjacent EC migration plays a key role in repairing the damaged endothelium. However, the underlying mechanisms are still unclear. In this study, we demonstrated that endothelium damage could activate XBP1 splicing in a VEGF signalling dependent manner, and that XBP1s not only regulated eNOS expression but also formed a complex with eNOS and Akt, which may contribute to endothelium damage-induced EC migration.

Endothelium damage *in vivo* usually induces platelet aggregation releasing platelet-derived growth factors and activates adjacent ECs secreting growth factors to increase the adjacent EC proliferation and migration in a paracrine and/or autocrine manner[35-38]. During this process, VEGF may play a vital role. Endogenous VEGF expression and its autocrine action could be regulated by other growth factors[39]. Our previous studies have demonstrated that VEGF can activate *XBPI* splicing through VEGF receptor 2, the kinase insert domain receptor (KDR) interaction with IRE1 α [25]. In this study, we found that the wound-induced *XBPI* splicing in HUVECs was blocked by KDR antagonist SU5416, suggesting that an active KDR signalling is essential. Several signalling pathways can be activated following KDR activation, of which the PI3K/Akt and MEK pathways are two serine/threonine kinase pathways[40]. However, the participation of these two signalling pathways in *XBPI* splicing seems different in wound healing and VEGF stimulation. In this study, these two signalling pathways seemed involved in scratching-induced *XBPI* splicing as the *XBPI* splicing was blocked by either PD98059 (MEK inhibitor) or LY294002 (PI3K/Akt inhibitor). However, both inhibitors had no effect on VEGF-induced *XBPI* splicing[25]. The discrepancy may reflect the fact that many growth factors can be secreted under scratching and there may be interaction among them. IRE1 α is normally activated by autophosphorylation at Ser/Thr sites[41]. The involvement of the Ser/Thr kinase MEK or PI3K/Akt in *XBPI* splicing suggests that these kinases may directly activate IRE1 α phosphorylation, which needs detailed investigation.

The eNOS expression and NO production play an essential role in the maintenance of vascular homeostasis[4, 42, 43]. Dysfunction in eNOS activity may lead to endothelial dysfunction, which is associated with cardiovascular diseases such as hypertension and atherosclerosis[44]. It has been reported that there is link between ER stress and NO production[45, 46]. However, the direct crosstalk between eNOS and *XBPI* splicing remains unknown. In this study, we demonstrated for the first time that *XBPI*s not only regulates *NOS3* mRNA and eNOS protein expression and NO production but also physically interacts with eNOS. *XBPI*s increased *NOS3* mRNA stability through down-regulating *miR-24*, which has a binding element in *NOS3* mRNA 3'UTR and directs *NOS3* mRNA degradation. The increased stability of *NOS3* mRNA may activate a feedback transcriptional suppression of *NOS3* gene, in which *XBPI*s is involved.

eNOS protein is an enzyme with multiple functions. Coupling with co-factors, eNOS catalyses L-Arginine to produce NO, while under uncoupling conditions, eNOS produces

reactive oxide species[47, 48]. eNOS can also serve as a co-activator regulating gene transcription[49, 50]. In this study, we found that scratching of EC monolayer increased eNOS protein and NO production in an *XBP1* splicing dependent manner, and that over-expression of *XBP1s* increased eNOS protein and NO production. The delay of NO production following scratching-induced EC migration indicates that NO may play a less important role in EC migration, especially in *XBP1s*-induced EC migration. Indeed, the suppression of NO production via L-NAME had no effect on *XBP1s*-induced EC migration. Very importantly, in this study we found that *XBP1s* physically interacted with eNOS protein and Akt in the nucleus, suggesting that eNOS may act as co-activator or co-repressor of *XBP1s* and participate in gene transcriptional regulation. Further detailed investigation on identifying the target genes of the *XBP1s*/eNOS/Akt complex will surely extend the functions of both eNOS and *XBP1*.

In summary, endothelium damage triggers the paracrine/autocrine secretion of growth factors from the adjacent ECs, which may include VEGF. The activation of VEGF receptor KDR and the downstream MEK and PI3K/Akt pathways contribute to IRE1 α -mediated *XBP1* splicing. The *XBP1s* down-regulates *miR-24* transcription, which increases *NOS3* mRNA stability. The elevated *NOS3* mRNA may drive *XBP1s* to suppress *NOS3* transcription via a feedback way on one hand, and increases eNOS protein level and NO production on the other hand. eNOS protein forms a complex with *XBP1s* and Akt, directing gene transcriptional regulation. The overall is to increase adjacent EC migration to repair damaged endothelium (Figure 6). This study adds new evidence on the role of *XBP1* splicing in angiogenesis through up-regulating EC proliferation and migration.

Experimental procedures

Materials

All cell culture serum and media were purchased from Gibco, while cell culture supplements were purchased from Sigma. The antibody against Flag (ab190059) was from Abcam. The antibodies against *XBP1* (M-186, sc-7160), IRE1 α (sc-20790), eNOS (sc-376542), Akt1/2/3 (sc-81434) and GAPDH (sc-25778) were from Santa Cruz Biotech. All secondary antibodies were from Dako Cytomation. All microRNA reagents were purchased from Thermo Fisher Scientific. SU1498, L-NAME, LY294002, KT-5823, DMSO, DAPI, crystal violet and Nitrite/Nitrate Assay Kit (23479) were purchased from Sigma.

Cell Culture

Human umbilical vein ECs (HUVECs, ATCC-PCS-100-010) were cultured on 0.04% gelatin-coated flasks in M199 medium supplemented with 1ng/ml β -EC growth factor, 3 μ g/ml EC Growth Supplement from bovine neural tissue, 10u/ml heparin, 1.25 μ g/ml thymidine, 10% FBS, 100u/ml penicillin and streptomycin in humidified incubator supplemented with 5% CO₂. The cells were split every three days at a ratio of 1:5.

Adenoviral and shRNA lentiviral infection

For adenoviral infection, HUVECs were incubated with Ad-null, or Ad-*XBP1u* (unspliced XBP1) or Ad-*XBP1s* (spliced XBP1) virus at 10 multiplicity of infection (MOI) for 6h, and then cultured in fresh complete growth medium for time duration indicated in figure legends. For the tetracycline inducible system, HUVECs were co-infected with Ad-*TRE-XBP1s* (10MOI) and Ad-*Tet-on* (2MOI) viruses for 6h and cultured for the time duration as indicated in figure legends. On the induction of XBP1s expression, 1 μ g/ml doxycycline was added into the culture medium and incubated for time duration as indicated in the figure legends. For shRNA lentiviral infection, HUVECs were incubated with 100 transfection unit/cell of non-target shRNA or *XBP1 shRNA* or *IRE1 α shRNA* lentivirus in the presence of 10mg/mL polybrene for 16h, followed by culture in fresh complete growth medium for 72h and subjected to further treatments.

Wound healing migration assay.

Wound was created by scratching confluent HUVECs in 6-well plates with 1ml tip. After removal of the cell debris and medium, fresh M199 medium containing 0.5% FBS was added and incubated for 6 hr. For the observation of cell migration, three scratching lines were created in each of three wells. Images were taken with at three different sites on each scratching line at 0 hr and 6 hr. The average migrated cells were calculated from 3 sites/line x 3 lines/well x 3 wells. For the assessments on RNA or protein samples, 10 (vertical) x 10 (horizontal) scratching lines were introduced into confluent HUVECs in ϕ 100mm dishes.

Trans-well migration assay

The transfected and/or infected HUVECs were detached by using trypsin and resuspended in M199 containing 0.5% FBS. A 100 μ l of 1×10^5 cells/ml cell suspension was added into the insert and 600 μ l of M199 containing 0.5% FBS was added into the holder of the trans-well (8 μ m pore size), followed by incubation for 6 hr. The cells were then fixed with 4% paraformaldehyde (Sigma) for 15 minutes, and stained with crystal violet solution for 15 minutes. After removal of the cells inside the insert, the migrated cells were observed under Nikon Eclipse TS100 microscope and images were taken by Nikon Digital Sight system and processed with Adobe Photoshop software. Cells were calculated from 10 view/well x 3 wells using 10x or 20x lenses.

Tube formation assay

The tube formation assay was performed as described previously [51]. Briefly, 100 μ l/well of growth factor-reduced Matrigel solution (Millipore) was added to 8-well chamber plate and solidified at 37 °C. 1×10^5 shRNA lentivirus-infected HUVECs (72h) were resuspended in 100 μ l M199 medium supplemented

with 5µg/ml VEGF or 0.1% BSA and added tomatrigel containing wells in triplicate and incubated in 37 °C humidified incubator supplemented with 5% CO₂ for 6h. Tube formation was observed under Nikon Eclipse TS100 microscope and images were taken by Nikon Digital Sight system and processed with Adobe Photoshop software. Tube numbers were calculated from 10 view/well x 3 wells using 10x lenses.

NO detection

Scratching(3x3) was introduced into confluent HUVEC monolayer in 6-well plates. After removal of the cell debris, fresh M199 medium was added and incubated for time duration as indicated in the figure legends. The cell medium was collected and spun at 2000xg at 4°C for 5 minutes to remove cell debris. Eighty µl/well of supernatant were added to 96-well plate in triplicate and subjected to total NO [NO₃- + NO₂-] detection with Nitrite/Nitrate Assay Kit (Sigma) according to the protocol provided.

MicroRNA analysis

The cellular total RNA was isolated with mirVana™ miRNA isolation kit according to the manufacturer's instruction. The reverse transcription of miRNAs was performed with the Applied Biosystems® TaqMan® MicroRNA Reverse Transcription kit and Applied Biosystems® 5x RT primer. The quantitative PCR amplifications of samples were done via Applied Biosystems® TaqMan® Universal PCR Master Mix, No AmpErase® UNG and 20x TaqMan small RNA Assay with protocol provided.

Pre-mir RNAs and siRNA transfection

For transient transfection assay, HUVECs were seeded in 6-well plates at 5×10^4 cells/well in triplicate 24h prior to transfection and treated with serum and antibiotics free M199 medium 1h prior to transfection. Twenty pmol of pre-miRNAs were transfected into HUVECs with 9µl of lipofectamine RNAiMax (Thermo Fisher Scientific) according to the procedure provided. Six hours later, the transfection solution was removed and fresh complete growth medium was added and the cells were incubated and subjected to further treatment as indicated in the figure legends. For siRNA transfection assay, HUVECs were seeded in 25ml flasks 24h prior to transfection and treated with serum and antibiotics free M199 medium for 1h prior to transfection. Ten µl of 10µmol/L control siRNA or *NOS3 siRNA* (sc-36093) was transfected into HUVECs using 12µl of Lipofectamine RNAiMax (Invitrogen) according to the protocol provided. Fresh complete growth medium was added 6h post transfection and incubated for 48h. The cells were infected with Ad-null or Ad-*XBPI*s virus at 10 MOI and incubated for 24 h, followed by trans-well migration assay.

Luciferase Activity Assay

HUVECs were seeded in 12-well plate at 5×10^4 cells/well 24h prior to transfection. HUVECs were transfected with (1) 0.1µg/well of pGL3-*NOS3-Luc* reporter and 0.02µg/well of Renilla-Luc (internal control) together with 0.1µg/well of pShuttle2-*XBPI*s, pShuttle2-*XBPI*u or pShuttle2-*ATF6N* expression plasmids or (2) 0.1µg/well of psiCHECK2-*TV1-3UTR* or psiCHECK2-*TV4-3UTR* reporter together with 0.1µg/well of pShuttle2-*XBPI*s and incubated for 36h, followed by luciferase activity assay. pShuttle2

plasmid was included as vector control (Mock). The relative luciferase activity (RLA) was defined as the ratio of the reporter luciferase activity to the internal control luciferase activity with that of mock group set as 1.0.

Immunoprecipitation and Immunoblotting

Immunoprecipitation and immunoblotting were performed according to standard procedures described elsewhere. Briefly, the cells were lysed with IP-A buffer [10 mM Tris-HCl, pH7.5, 120 mM NaCl, 1 mM EDTA, 1% Triton X-100 plus protease inhibitor cocktail tablets (one tablet for 50 mL, Roche)] and the protein concentration was measured by BioRad protein assay (BioRad). One milligram lysate was mixed with 10 μ l of anti-FLAG-agarose beads (Sigma) and 3 volumes of IP-B buffer (IP-A buffer without Triton X-100) and incubated on a rotator at 4°C for 4h, followed by SDS-PAGE and standard Western blot analysis. For the input control or routine Western blot, SDS-denatured 50 μ g lysate was applied to SDS-PAGE. After transferring to PVDF membrane (Amersham), the target protein bands were detected with primary and secondary antibodies incubation, ECL development and X-ray film exposure (Amersham). The images were processed by Adobe Photoshop software.

RT-PCR and qPCR

The total cellular RNA was extracted using Qiagen RNeasy Kit according to the protocol provided. Two microgram RNA was transcribed into cDNA using Improm-II reverse transcription system (Promega). For realtime PCR (qPCR), 20ng cDNA was amplified by a real time PCRSYBR master mix (Applied Biosystems). Primers for qPCR were designed with the Primer Express Software (Applied Biosystems) as follows: *XBPIu* (forward) 5'-tgctgagtcgccgagcactag-3', *XBPIs* (forward) 5'-tgctgagtcgccgagcaggtg-3' and a common reverse primer 5'-gctggcaggctctggggaag-3'; *NOS35'* aggaacctgtgtgacctca -3' and 5' -cgaggtgtccgggtatcc -3'; β -actin 5'-cacaactgggacgacatggag-3' and 5'-tcatgaggtagtcagtctgg-3' as internal control.

Immunofluorescence staining

The cells on slides were fixed with 4% paraformaldehyde at room temperature (RT) for 15min and permeabilised with 0.1% Triton X-100/PBS at RT for 15min, followed by blocking with diluted normal serum (1:20) for 1h, incubation with diluted primary and secondary antibodies at 37°C for 1h and 45min, respectively. Nucleus was counterstained with DAPI. Images were taken by using SP5 confocal microscope (Leica, Germany) and processed by Adobe Photoshop software.

Statistical Analysis

Data expressed as the mean \pm S.E. were analyzed using GraphPad Prism software (version 6) with t test for pair-wise comparisons or analysis of variance, when t test was inappropriate, followed by Dunnett's multiple comparison tests, and significance was depicted by asterisks (*, $p < 0.05$; **, $p < 0.01$).

Acknowledgements

This study was supported by British Heart Foundation and Chinese scholarship Council.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Author contribution

W.W. and L.S. conceived the studies, J.Y. conducted the majority of the experiments, and J.X. contributed to image taking by confocal microscope and X.W. contributed to cell culture. The manuscript was written by J.Y. and revised by L.S.

Accepted manuscript

References

- [1] Jain RK. Molecular regulation of vessel maturation. *Nature medicine*. 2003;9:685-93.
- [2] Lao KH, Zeng L, Xu Q. Endothelial and smooth muscle cell transformation in atherosclerosis. *Current opinion in lipidology*. 2015;26:449-56.
- [3] Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;93:13176-81.
- [4] Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation*. 2006;113:1708-14.
- [5] Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. *The Journal of clinical investigation*. 1998;101:731-6.
- [6] Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. *Circulation*. 2001;104:448-54.
- [7] Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350-5.
- [8] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004;116:281-97.
- [9] Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. *Circulation*. 2011;124:720-30.
- [10] Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson AS, O'Callaghan P, Heindryckx F, et al. MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA). *The Journal of biological chemistry*. 2013;288:25956-63.
- [11] Song BW, Kim IK, Lee S, Choi E, Ham O, Lee SY, et al. 1H-pyrrole-2,5-dione-based small molecule-induced generation of mesenchymal stem cell-derived functional endothelial cells that facilitate rapid endothelialization after vascular injury. *Stem cell research & therapy*. 2015;6:174.
- [12] Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, et al. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. *Science (New York, NY)*. 1990;247:1581-4.
- [13] Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. *Cancer research*. 2004;64:5943-7.
- [14] Shen X, Ellis RE, Lee K, Liu CY, Yang K, Solomon A, et al. Complementary signaling pathways regulate the unfolded protein response and are required for *C. elegans* development. *Cell*. 2001;107:893-903.
- [15] Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell*. 2001;107:881-91.
- [16] Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. *Physiological reviews*. 2006;86:1133-49.
- [17] Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science (New York, NY)*. 2004;306:457-61.
- [18] Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell death and differentiation*. 2004;11 Suppl 1:S56-64.
- [19] Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. *Clinical biochemistry*. 2003;36:431-41.
- [20] Gargalovic PS, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. *Arteriosclerosis, thrombosis, and vascular biology*. 2006;26:2490-6.

- [21] Sharma P, Senthilkumar RD, Brahmachari V, Sundaramoorthy E, Mahajan A, Sharma A, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. *Lipids in health and disease*. 2006;5:1.
- [22] Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS, et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. *Circulation*. 2004;110:207-13.
- [23] Uemura A, Oku M, Mori K, Yoshida H. Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the mammalian unfolded protein response. *Journal of cell science*. 2009;122:2877-86.
- [24] Zeng L, Zampetaki A, Margariti A, Pepe AE, Alam S, Martin D, et al. Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106:8326-31.
- [25] Zeng L, Xiao Q, Chen M, Margariti A, Martin D, Ivetic A, et al. Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis. *Circulation*. 2013;127:1712-22.
- [26] Oliver BL, Cronin CG, Zhang-Benoit Y, Goldring MB, Tanzer ML. Divergent stress responses to IL-1beta, nitric oxide, and tunicamycin by chondrocytes. *Journal of cellular physiology*. 2005;204:45-50.
- [27] Takada K, Hirose J, Yamabe S, Uehara Y, Mizuta H. Endoplasmic reticulum stress mediates nitric oxide-induced chondrocyte apoptosis. *Biomedical reports*. 2013;1:315-9.
- [28] Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. *Arteriosclerosis, thrombosis, and vascular biology*. 1999;19:1156-61.
- [29] Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. *The American journal of pathology*. 2000;156:1469-76.
- [30] Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. *The Journal of biological chemistry*. 1995;270:27489-94.
- [31] Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *The Journal of biological chemistry*. 1994;269:5241-8.
- [32] Kawasaki K, Smith RS, Jr., Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. *Molecular and cellular biology*. 2003;23:5726-37.
- [33] Borniquel S, Garcia-Quintans N, Valle I, Olmos Y, Wild B, Martinez-Granero F, et al. Inactivation of Foxo3a and subsequent downregulation of PGC-1 alpha mediate nitric oxide-induced endothelial cell migration. *Molecular and cellular biology*. 2010;30:4035-44.
- [34] Pfeiffer S, Leopold E, Schmidt K, Brunner F, Mayer B. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. *Br J Pharmacol*. 1996;118:1433-40.
- [35] Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. *Int J Lab Hematol*. 2013;35:254-61.
- [36] Passaretti F, Tia M, D'Esposito V, De Pascale M, Del Corso M, Sepulveres R, et al. Growth-promoting action and growth factor release by different platelet derivatives. *Platelets*. 2014;25:252-6.
- [37] Hannan RL, Kourembanas S, Flanders KC, Rogelj SJ, Roberts AB, Faller DV, et al. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. *Growth Factors*. 1988;1:7-17.
- [38] McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. *Clin Appl Thromb Hemost*. 1999;5:21-4.

- [39] Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. *J Pharmacol Exp Ther*. 2001;299:1073-85.
- [40] Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. *Nat Rev Drug Discov*. 2016;15:385-403.
- [41] Iwawaki T, Hosoda A, Okuda T, Kamigori Y, Nomura-Furuwatari C, Kimata Y, et al. Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress. *Nat Cell Biol*. 2001;3:158-64.
- [42] Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. *American journal of physiology Heart and circulatory physiology*. 2011;301:H634-46.
- [43] Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. *Handbook of experimental pharmacology*. 2006:213-54.
- [44] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980;288:373-6.
- [45] Yang L, Calay ES, Fan J, Arduini A, Kunz RC, Gygi SP, et al. METABOLISM. S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction. *Science (New York, NY)*. 2015;349:500-6.
- [46] Husa M, Petursson F, Lotz M, Terkeltaub R, Liu-Bryan R. C/EBP homologous protein drives pro-catabolic responses in chondrocytes. *Arthritis Res Ther*. 2013;15:R218.
- [47] Chen CA, Lin CH, Druhan LJ, Wang TY, Chen YR, Zweier JL. Superoxide induces endothelial nitric-oxide synthase protein thiyl radical formation, a novel mechanism regulating eNOS function and coupling. *J Biol Chem*. 2011;286:29098-107.
- [48] Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. *Circulation research*. 2005;97:864-71.
- [49] Grasselli A, Nanni S, Colussi C, Aiello A, Benvenuti V, Ragone G, et al. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. *Circulation research*. 2008;103:34-42.
- [50] Zeng L, Xu Q. eNOS-ERalpha complex goes to telomerase. *Circulation research*. 2008;103:10-2.
- [51] Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S, et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. *The Journal of cell biology*. 2006;174:1059-69.




Figure 1. XBP1 splicing contributed to EC migration. (A) Wound induced XBP1 splicing. Wound was introduced into a confluent HUVEC monolayer by scratching, followed by observation of cell migration and western blot analysis of the spliced XBP1 (XBP1s) protein at 6h and 24h post-scratching. GAPDH was included as loading control. Scale bar: 100 μ m. (B) Over-expression of XBP1s enhanced EC wound healing. Confluent HUVECs were infected with Ad-null or Ad-XBP1s virus at 10 MOI for 24h, followed by scratching and observation of wound healing at time indicated. (C-E) Knockdown of XBP1 or IRE1 α attenuated wound healing and tube formation. XBP1 splicing could be down-regulated by XBP1 shRNA (XBP1sh) or IRE1 α shRNA (IRE1 α) lentiviruses as revealed by Western blot (C). The lentivirus-infected HUVECs (for 72h) were subjected to wound healing assays (D) or tube formation on Matrigel assays in the absence or presence of 10ng/ml VEGF (E). Non-target shRNA (NTsh) lentivirus and 1% BSA were included as control. The relative

migrated area (RMA) was defined as the percentage of the area occupied by the migrated cells to that of the empty area created by the scratching. The data presented were representative images or average of three independent experiments. Scale bar: 100 μ m. *: $p < 0.05$; **: $p < 0.01$.




Figure 2. Wound in EC monolayer up-regulated eNOS expression in an XBP1 splicing-dependent manner. (A-B) Wound increased eNOS protein level (A) and NO production (B). Wound was introduced into a confluent HUVEC monolayer via scratching, followed by Western blot analysis of eNOS protein level (A) and NO production assay (B) at time

indicated post-scratching. **(C)** Inhibition of the VEGF signalling pathway abolished wound-induced *NOS3* expression. The confluent HUVEC monolayer was pre-treated with inhibitors for 1h, then subjected to scratching and incubation in the presence of inhibitors for 6hr, followed by quantitative RT-PCR analysis of *NOS3* mRNAs. DMSO (DM) was included as vehicle control. SU: SU1498, PD: PD98059, LY: LY294002. **(D)** Knockdown of *XBP1* or *IRE1α* abolished wound-induced *NOS3* upregulation. HUVECs were infected with non-target (*NTsh*), *XBP1* (*XBP1sh*) or *IRE1α* (*IRE1αsh*) shRNA lentivirus for 72h, followed by scratching and quantitative RT-PCR analysis of *XBP1u*, *XBP1s* and *NOS3* mRNA levels at 6h post-scratching. **(F-G)** Overexpression of XBP1s increased eNOS protein level and NO production. HUVECs were infected with Ad-*TRE-XBP1s* (10 MOI) together with Ad-Tet (2 MOI) for 24h, and then treated with 1ug/ml doxycycline (Dox) for time indicated, followed by Western blot analysis (F) and NO production assay (G). Ad-null was included as control. Anti-FLAG was included to indicate XBP1s expression. GAPDH was included as loading control. The data presented were representative images or average of three independent experiments. *: $p < 0.05$.




Figure 3. XBP1s increased NOS3 mRNA stability via miR-24. (A) XBP1s suppressed pGL3-NOS3-Luc reporter expression. The relative luciferase activity (RLA) was defined as the ratio of firefly luciferase to renilla luciferase activity with that of mock group set as 1.0. (B) XBP1s increased pSiCHECK2-TV1-3'UTR and pSI-CHECK2-TV4-3'UTR reporter expression. The relative luciferase activity (RLA) was defined as the ratio of renilla luciferase to firefly luciferase activity with that of mock group set as 1.0. (C) Scratching down-regulated miR-24, miR-125 and miR-214 in an XBP1 splicing dependent manner. Quantitative RT-PCR analysis of miR-24, miR-125, miR-214 levels was performed at 6h post scratching. (D) Scratching increased miR-125 and miR-214 degradation. PremiRs (pmir) were introduced into HUVECs and subjected to scratching, followed by quantitative analysis of the miRNAs levels. (E) Over-expression of XBP1s down-regulated miR-24. HUVECs were infected with Ad-XBP1s (10 MOI) for 24h, followed by quantitative RT-PCR analysis. (F) Exogenous premiR-24 (pmir24) abolished scratch-induced NOS3 mRNA upregulation. (G) Exogenous miR-24 abolished XBP1s-induced eNOS expression. HUVECs were

transfected with 10pmol/well premiR24, premiR125 and premiR214 respectively. 48h later, the transfected cells were infected with Ad-null or Ad-TRE-XBP1s/Ad-Teton virus at (10/2) MOI for 24h, and then treated with 1ug/ml doxycycline (Dox) for 1h, followed by Western blot analysis of eNOS and FLAG-tagged XBP1s expression. The data presented were representative images or average of three independent experiments. *: $p < 0.05$.




Figure 4. miR-24 was involved in XBP1s-induced ECs migration. HUVECs were transfected with premiR24 for 6h, then infected with Ad-XBP1s (10 MOI) for 24h, followed by transwell migration assays (A) and wound healing assays (B). The relative migrating area (RMA) was defined as the percentage of the area occupied by the migrated cells to that of the empty area created by the scratching. Scale bar: 100 μ m. The data presented were representative images or average of three independent experiments. *: $p < 0.05$.




Figure 5. eNOS was involved in EC migration via forming a complex with AKT and XBP1s. (A) LY294002 but not L-NAME abolished XBP1s-induced EC migration. HUVECs were infected with Ad-null or Ad-XBP1s virus at 10 MOI for 24h, then pretreat with LY294002 (5 μ mol/L) and L-NAME (100 μ mol/L) for 2h, followed by trans-well migration assay in the presence of inhibitors for 6h. Migrated cells were calculated using 20x lenses view. DMSO was included as vehicle control. Scale bar: 25 μ m. (B) Knockdown of NOS3 abolished XBP1s-induced ECs migration. HUVECs were transfected with NOS3 siRNAs for 48h, then infected with Ad-XBP1s for 24hr, followed by trans-well migration assay. Migrated cells were calculated using 10x lenses view. Control siRNA (ctlsi) and Ad-null were included as control. Scale bar: 50 μ m. (C) XBP1s, eNOS and Akt formed a complex. anti-Flag antibody was used to pulldown and detect XBP1s. (D) XBP1s, eNOS and Akt co-localised in the nucleus. Triple immunofluorescent staining was performed in Ad-null and

Ad-XBP1s infected HUVECs with anti-FLAG (green, for XBP1s), Akt (red), eNOS (purple). The nucleus was counter-stained with DAPI (blue). Scale bar: 10 μ m. The data presented were representative images or average of three independent experiments. *: $p < 0.05$.






Figure 6. The interaction between XBP1 and eNOS contributes endothelium damage-induced EC migration. Endothelium damage activates VEGF receptor KDR in the adjacent ECs in a VEGF dependent or independent manner, which in turn activates IRE1 α -mediated XBP1 mRNA unconventional splicing, removing a 26 nucleotide (nt) and causing the open reading frame to shift to produce a transcriptionally active isoform, the XBP1s. XBP1s suppresses miR-24 transcription on one hand, leading to NOS3 mRNA stabilisation, eNOS protein and NO production increase. The elevated NOS3 mRNA may drive XBP1s


suppressing NOS3 transcription in a feed-back way. On the other hand, XBP1s may be involved in Akt activation and facilitate the nuclear relocation of Akt and eNOS protein to form an Akt/XBP1/eNOS complex in the nucleus, which may be involved in the transcription of genes that are involved in cell migration regulation. The overall effect is to increase the adjacent EC migration to repair the damaged endothelium.



Supplement 1. Wound in EC monolayer induced XBP1 splicing in a VEGF signalling pathway dependent manner. VEGF signalling pathway inhibitors abolished the scratching-induced XBP1 splicing. The confluent HUVEC monolayer was treated with inhibitors for 1h, then subjected to scratching and incubation in the presence of inhibitors for 6hr, followed by quantitative RT-PCR analysis of the unspliced (*XBP1u*) and spliced (*XBP1s*) *XBP1* mRNAs. DMSO (DM) was included as vehicle control. SU: SU5416 (5 μ mol/L), PD: PD98059 (5 μ mol/L), LY: LY294002 (5 μ mol/L). The data presented were representative images or average of three independent experiments. *: $p < 0.05$.



Supplement 2. XBP1 splicing induced endothelial cell migration is PKG independent.(A) HUVECs were infected with Ad-XBP1s (10 MOI) for 24h, followed by Western blot analysis. (B) Infected HUVECs then pretreat with KT-5823(5 μ mol/L for 2h, followed by trans-well migration assay in the presence of inhibitors for 6h. Migrated cells were calculated using 20x lenses view. DMSO was included as vehicle control. Scale bar: 25 μ m. The data presented were representative images or average of three independent experiments. *: p<0.05.



Supplement 3: eNOS was involved in EC migration via forming a complex with AKT and XBP1s.(A)XBP1s, eNOS and Akt formed a complex with the treatment of VEGF. Anti-XBP1s antibody was used to pulldown. (B, C) XBP1s, eNOS and Akt co-localized in the nucleus. Triple immunofluorescent staining was performed in scratched (B) and VEGF(C) treated HUVECs with anti-Akt1/2 (red); anti-NOS3 (green), anti-XBP1s (gray). The nucleus was counter-stained with DAPI (blue). Scale bar: 10 μ m. The data presented were representative images or average of three independent experiments. *: $p < 0.05$.

Abbreviations

X-box binding protein 1 (XBP1)

vascular endothelial growth factor (VEGF)

endothelial cell (EC)

XBP1 (XBP1s)

nitric oxide synthase 3 (*NOS3*)

adenovirus -XBP1s (Ad-XBP1s)

Protein kinase B (Akt)

nitric oxide synthase 3 (NOS3)

nitric oxide (NO)

basic-region leucine zipper (bZIP)

inositol requiring enzyme 1 alpha (IRE1 α)

endoplasmic reticulum (ER)

unsplicedXBP1 (XBP1u)

human umbilical vein EC (HUVEC)

NOS3 promoter reporter expression (pGL3-*NOS3*-Luc reporter)

mature activating transcription factor 6 (ATF6N)

NG-nitro-L-arginine methyl ester (L-NAME)

the kinase insert domain receptor (KDR)

doxycycline (Dox)\

Dimethyl sulfoxide (DMSO, DM)

Highlights

- Wound in EC monolayer induced XBP1 splicing, which was involved in EC migration.
- XBP1s increased NOS3 mRNA stability via down-regulating microRNA miR-24.
- ENOS was involved in EC migration via forming a complex with AKT and XBP1s.